A landmark clinical trial shows a new pancreatic cancer drug significantly improved survival rates in participants who'd been previously treated with chemotherapy. The success of the experimental pill, daraxonrasib, signifies a major breakthrough in pancreatic cancer treatment.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| We talked to your gut - it thinks you need this newsletter in you life. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Until then, |
 |
Take care of yourself, and we’ll
see you again soon! |
|
|
|
|
View in browser
Did a friend send you this email? Subscribe here.
To see all newsletters, click here.
Privacy | Unsubscribe
We may feature your messages to our inbox within our content. Please do not provide any personal identifiable information. Replies may be edited for length and clarity. For more, see our Privacy Policy.
Our website services, content, and products are for informational purposes only. Healthline does not provide medical advice, diagnosis, or treatment and should not be used as a substitute for medical advice from a healthcare professional. Healthline encourages you to make any treatment decisions with your healthcare professional.
Every product we recommend has gone through either Healthline’s or Optum Now’s vetting processes. If you buy through links on this page, we may receive a small commission or other tangible benefit. Healthline has sole editorial control over this newsletter. Potential uses for the products listed here are not health claims made by the manufacturers. Healthline and Optum Now are owned by RVO Health.
© 2026 RVO Health
1101 Red Ventures Drive
Fort Mill, SC 29707 |
|
|
|
No comments:
Post a Comment